NewsBenzingaAB InBev prevede per l’esercizio 2026 una crescita dell’EBITDA del 4-8%, costi finanziari netti trimestrali di 190-220 milioni di dollari, capex netto di 3,5-4,0 miliardi di dollari, escluse le variazioni della normativa fiscale AB InBev prevede per l’esercizio 2026 una crescita dell’EBITDA del 4-8%, costi finanziari netti trimestrali di 190-220 milioni di dollari, capex netto di 3,5-4,0 miliardi di dollari, escluse le variazioni della normativa fiscale Benzinga 2026.10.29 06:20 (GMT+0) Open on Benzinga Other news BBVA Q3 Adj. EPS $0.61 Misses $0.62 Estimate, Sales $12.560B Miss $12.580B Estimate MSFT Stock Eyes Best Day In Over 3 Months After Earnings Beat — Gene Munster Says 'Software Is Alive And Well, At Least For Now' ING Groep Q3 EPS $0.75 Misses $0.79 Estimate, Sales $7.167B Beat $7.000B Estimate Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate Takeda Pharmaceutical Co Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131
MSFT Stock Eyes Best Day In Over 3 Months After Earnings Beat — Gene Munster Says 'Software Is Alive And Well, At Least For Now'
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
